Idiopathic pulmonary fibrosis (IPF) is associated with a substantial economic burden in the United States, especially for patients who…
Articles by Margarida Azevedo, MSc
Patients with interstitial lung disease (ILD), including pulmonary fibrosis (PF), have an increased risk of coronary heart disease…
Hepion Pharmaceuticals‘ CRV431 has a similar, or even greater effect in reducing markers of idiopathic pulmonary fibrosis…
Researchers at the University of Pittsburgh and the University of Delaware received funding for their research into innovative therapies…
The U.S. Food and Drug Administration (FDA) has cleared Paragonix Technologies’ request that LUNGguard, its preservation system for transporting…
Veracyte, Inc., presented new data indicating that its in-development genomic test, the Envisia classifier, has the potential to diagnosis idiopathic pulmonary…
Veracyte, Inc., recently announced that data from multiple studies supporting the ability of its diagnostic tests to help detect pulmonary disease, including…
ProterixBio, Inc., is the new name for the company previously known as BioScale, Inc., reflecting a change in strategy.
Researchers at Yale School of Medicine, Boston University School of Medicine, and other institutions applied an integrative genomic approach to…
FibroGen, Inc., recently disclosed potentially groundbreaking results from a Phase 2 clinical trial evaluating the efficacy of the company’s investigational drug…